PubRank
Search
About
Elaine Coustan-Smith
Author PubWeight™ 79.50
‹?›
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.
Nature
2007
17.68
2
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
Nature
2012
9.89
3
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
N Engl J Med
2009
7.95
4
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Nat Genet
2009
4.35
5
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Lancet Oncol
2010
3.76
6
Primary B cell immunodeficiencies: comparisons and contrasts.
Annu Rev Immunol
2009
2.97
7
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.
Blood
2012
2.55
8
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.
Blood
2007
2.19
9
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
Blood
2012
2.14
10
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.
Blood
2011
1.68
11
Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.
J Exp Med
2012
1.66
12
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
J Clin Oncol
2011
1.52
13
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.
Blood
2010
1.47
14
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.
Blood
2006
1.41
15
Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR.
Br J Haematol
2005
1.35
16
Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase.
Br J Haematol
2003
1.33
17
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.
J Clin Oncol
2014
1.31
18
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
J Clin Oncol
2012
1.30
19
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
Cytotherapy
2012
1.27
20
Improved prognosis for older adolescents with acute lymphoblastic leukemia.
J Clin Oncol
2010
1.16
21
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15.
Br J Haematol
2011
1.10
22
Minimal residual disease quantitation in acute myeloid leukemia.
Clin Lymphoma Myeloma
2009
1.07
23
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
Cancer
2013
0.98
24
Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia.
Haematologica
2006
0.98
25
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
Cancer
2008
0.95
26
Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
Best Pract Res Clin Haematol
2002
0.94
27
Minimal residual disease studies by flow cytometry in acute leukemia.
Acta Haematol
2004
0.91
28
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.
Br J Haematol
2014
0.84
29
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Cancer
2014
0.84
30
Measurements of treatment response in childhood acute leukemia.
Korean J Hematol
2012
0.84
31
Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.
Blood
2011
0.83
32
Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells.
Haematologica
2002
0.80
33
Minimal residual disease monitoring by flow cytometry.
Best Pract Res Clin Haematol
2003
0.80
34
WT1 protein expression in childhood acute leukemia.
Am J Hematol
2008
0.79
35
Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.
Pediatr Blood Cancer
2013
0.75